We report a case of a patient with gastric carcinoma who developed delayed-onset TEN after receiving four cycles of neoadjuvant sintilimab combined with the SOX regimen (S-1 and oxaliplatin)...Early recognition and timely immunosuppressive treatment are essential for favorable outcomes. Further investigation into the mechanisms and predictive factors of PD-1 inhibitor-induced TEN is warranted.

This trial indicates that ketotifen may offer a promising approach for preventing OIPN. Larger placebo-controlled, double-blind, multicenter trials are needed to confirm these findings.

Functional assays validated PTPN12's role in CRC cells and its impact on oxaliplatin resistance...PTPN12 shows promise as a potential biomarker and therapeutic target candidate in CRC. Our study provides preliminary insights into the role of PTPN12 in CRC pathogenesis, treatment response, and chemoresistance, which may lay the groundwork for future development of personalized therapeutic strategies pending further in vivo validation.

In vitro and in vivo models demonstrate that targeting GPX4 with the ferroptosis activator RSL3 restores chemotherapy sensitivity. These findings identify a novel mechanism of chemoresistance mediated by senEndo-derived GPX4 in extracellular vesicles and highlight the potential of ferroptosis induction, alone or in combination with senolytic agents, to improve 5-Fu/oxaliplatin-based CRC therapies.

Objective: To investigate the clinical efficacy, toxicity and prognosis of SOX regimen (Oxaliplatin plus S-1) combined with Pabolizumab in the treatment of patients with metastatic gastric cancer...There was no statistical difference in the incidence [67.9% (38/56) in chemotherapy group vs 78.4% (40/51) in combination group] of grade Ⅲ-Ⅳ toxicity between the two groups (P=0.219). In patients with PD-L1 CPS ≥1 or all enrolled patients, compared with chemotherapy alone, SOX regimen combined with pembrolizumab in the treatment of metastatic gastric cancer can significantly improve ORR, prolong PFS and OS, improve prognosis and quality of life, while the toxicity has not increased significantly.

Postoperatively, capecitabine and oxaliplatin (CAPOX) plus bevacizumab chemotherapy was initiated following colorectal cancer protocols. This rare case of primary upper jejunal adenocarcinoma presenting as a Krukenberg tumor underscores the importance of thorough diagnostic evaluation, including immunohistochemical analysis. Multidisciplinary management and timely surgical intervention remain essential for both diagnosis and symptom control in advanced SBA.

Compared with 5-fluorouracil, raltitrexed offers distinct pharmacokinetic and practical advantages, including prolonged intracellular retention and a short infusion schedule...Accumulating evidence from retrospective studies, prospective single-arm trials, and limited comparative analyses suggests that raltitrexed-based regimens demonstrate meaningful antitumor activity in conventional and drug-eluting bead TACE, as well as in oxaliplatin-based HAIC, with objective response rates, disease control, and survival outcomes comparable to established chemotherapy protocols...Overall, raltitrexed represents a rational and increasingly utilized component of arterial-based therapies for unresectable HCC. However, current evidence is predominantly derived from retrospective and single-arm studies, and well-designed randomized trials and biomarker-driven approaches are required to define its optimal role in clinical practice.

Patients received a regimen consisting of oxaliplatin, sintilimab, capecitabine, and IL‑2 administered in a three‑week cycle, with response evaluations performed after every two cycles. These findings warrant studies to validate this regimen as a novel treatment paradigm for rectal cancer. ClinicalTrials.gov registration: NCT06108596.

P=N/A, N=128, Suspended, Shandong Cancer Hospital and Institute | Recruiting --> Suspended

P=N/A, N=63, Completed, Washington University School of Medicine | Trial completion date: Apr 2026 --> Jan 2026 | Active, not recruiting --> Completed

Following neoadjuvant chemoimmunotherapy comprising XELOX and sintilimab, diagnostic laparoscopy identified a concurrent AMA accompanied by pseudomyxoma peritonei (PMP). This rare case highlights the critical importance of comprehensive preoperative imaging and meticulous surgical evaluation in the diagnosis of uncommon synchronous malignancies. Furthermore, the observed alteration in molecular phenotype following chemoimmunotherapy suggests that such treatment modalities may influence tumor biology.

P=N/A, N=57, Completed, Sengkang General Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2026